Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paralysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    418 result(s) found for: Paralysis. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-005658-66 Sponsor Protocol Number: P051072 Start Date*: 2006-12-27
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation de l'efficacité des corticoïdes dans la prévention de la paralysie faciale après chirurgie d'exérése d'une tumeur du méat auditif interne et /ou de l'angle ponto-cérébelleux
    Medical condition: Prévention de la paralysie faciale après chirurgie d'éxérèse d'une tumeur du méat auditif interne et/ou de l'angle ponto-cérébelleux.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033808 Oto-rhino-laryngologie, PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003817-15 Sponsor Protocol Number: XEO 02 ITA Start Date*: 2007-11-22
    Sponsor Name:AZIENDA SANITARIA LOCALE N 15 DI CUNEO
    Full Title: Prospective, open-label, multi-center trial to investigate efficacy and safety of Xeomin in the treatment of post-stroke spasticity in the lower limb
    Medical condition: Post-stroke patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052469 Postictal paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004195-36 Sponsor Protocol Number: 120542 Start Date*: 2014-07-21
    Sponsor Name:University College of London
    Full Title: A randomised, double-blind, placebo-controlled, phase II clinical trial with a cross-over design assessing efficacy of a single dose of bumetamide in reducing focal attack severity in hypokalaemic ...
    Medical condition: Hypokalaemic Periodic Paralysis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016208 Familial periodic paralysis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021410-34 Sponsor Protocol Number: EOC-2-Opht-2010 Start Date*: 2010-08-12
    Sponsor Name:Medical Centre Haaglanden
    Full Title: A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children
    Medical condition: Depth of cycloplegia; changes of astigmatism; recuperation from cycloplegia and mydriasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011719 Cycloplegia LLT
    12.1 10011719 Cycloplegia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002306-19 Sponsor Protocol Number: Hyp Hop Start Date*: 2010-02-10
    Sponsor Name:University of Rochester
    Full Title: Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis
    Medical condition: Patients with hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10016208 Familial periodic paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000801-30 Sponsor Protocol Number: E2007-G000-318 Start Date*: 2007-08-01
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) PL (Completed) FR (Completed) ES (Completed) IT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-018143-25 Sponsor Protocol Number: 2010 Start Date*: 2010-05-06
    Sponsor Name:Västra Götalandsregionen
    Full Title: An open label, historical control, study to assess the impact on bacteriological healing of Prednisolone in patients with neuroborreliosis-caused peripheral facial palsy receiving treatment with Do...
    Medical condition: Facialispares orsakad av CNS-infektion med Borrelia burgdorferi. (Neuroborrelios-orsakad facialispares)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052057 Neuroborreliosis LLT
    12.1 10016060 Facial palsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017182-38 Sponsor Protocol Number: IPX066-B09-03 Start Date*: 2010-05-14
    Sponsor Name:Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
    Full Title: An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease
    Medical condition: Idiopathic Parkinson´s disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002339-26 Sponsor Protocol Number: E2007-G000-303 Start Date*: 2006-10-05
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor ...
    Medical condition: Levodopa treated Parkinson's disease patients with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) CZ (Completed) HU (Completed) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) DE (Completed) ES (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002968-49 Sponsor Protocol Number: BN43118 Start Date*: 2022-06-24
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ S...
    Medical condition: Guillain-Barré syndrome (GBS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10018767 Guillain-Barre syndrome PT
    21.1 10029205 - Nervous system disorders 10018766 Guillain Barre syndrome LLT
    21.1 10029205 - Nervous system disorders 10042812 Syndrome Guillain-Barre LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005234-39 Sponsor Protocol Number: 2939111 Start Date*: 2005-05-27
    Sponsor Name:Orion Corporation, ORION PHARMA, Finland
    Full Title: Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) FI (Completed) IE (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-002697-37 Sponsor Protocol Number: 14/0382 Start Date*: 2015-04-15
    Sponsor Name:University College London
    Full Title: Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease
    Medical condition: Parkinson's Disease Nocturia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    17.1 10029205 - Nervous system disorders 10034007 Parkinson's disease NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011541-24 Sponsor Protocol Number: TVP-1012/501 Start Date*: 2009-10-09
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000148-40 Sponsor Protocol Number: PDSTAT2015 Start Date*: 2015-11-09
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    18.0 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000833-12 Sponsor Protocol Number: NW-1015/015/III/2003 Start Date*: 2004-12-02
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients ...
    Medical condition: Early idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000835-27 Sponsor Protocol Number: NW-1015/017/III/2003 Start Date*: 2004-12-03
    Sponsor Name:NEWRON PHARMACEUTICALS
    Full Title: A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with ear...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061536 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008210-38 Sponsor Protocol Number: 2008_02/0841 Start Date*: 2009-04-16
    Sponsor Name:Chru de Lille
    Full Title: Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”
    Medical condition: Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    9.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003784-94 Sponsor Protocol Number: MexLam Start Date*: 2022-01-20
    Sponsor Name:Rigshospitalet, department of Neurology
    Full Title: Treatment of Myotonia - Lamotrigine versus Namuscla
    Medical condition: Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10049841 Myotonia congenital LLT
    20.1 100000004850 10076440 Hyperkalemic periodic paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002769-30 Sponsor Protocol Number: 28780 Start Date*: 2009-04-30
    Sponsor Name:MERCK SERONO SA
    Full Title: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson�s dis...
    Medical condition: Parkinson Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 17:09:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA